Solutions
For Personal Use
For Health Professionals
For Schools
For Businesses
Resources
Variant Info
Expiration Extension
Insurance
Documents
Web App
Press Releases
Documentos en Español
FAQ
Contact Us
Where to Buy
Solutions
For Personal Use
For Health Professionals
For Schools
For Businesses
Resources
Variant Info
Expiration Extension
Insurance
Documents
Web App
Press Releases
Documentos en Español
FAQ
Contact Us
Where to Buy
Press Releases
INTELISWAB® COVID-19 RAPID TESTS RECEIVE U.S. FDA AUTHORIZATION FOR PEDIATRIC USE AND COMPANY LAUNCHES NEW INTELISWAB® CONNECT REPORTING APP
U.S. FDA AUTHORIZES INTELISWAB® COVID-19 RAPID TESTS FOR OTC SINGLE-USE, AT-HOME TESTING FOR SYMPTOMATIC PEOPLE AND ACCEPTS DATA FOR DELTA VARIANT DETECTION
ORASURE TO RECEIVE UP TO $13.6 MILLION FROM BIOMEDICAL ADVANCED RESEARCH DEVELOPMENT AUTHORITY TO SUPPORT INTELISWAB® COVID-19 RAPID TEST 510(K) CLEARANCE AND CLIA WAIVER
ORASURE RECEIVES $205 MILLION PROCUREMENT CONTRACT FOR INTELISWAB® FROM THE DEFENSE LOGISTICS AGENCY TO SUPPLY OVER-THE-COUNTER (OTC) KITS AS PART OF NATIONAL PANDEMIC RESPONSE
ORASURE TECHNOLOGIES RECEIVES THREE EMERGENCY USE AUTHORIZATIONS FOR ITS COVID-19 RAPID ANTIGEN TESTS FOR NON-PRESCRIPTION (OTC), PROFESSIONAL AND PRESCRIPTION USE
ORASURE TECHNOLOGIES SUBMITS COVID-19 RAPID ANTIGEN PRESCRIPTION HOME SELF-TEST AND PROFESSIONAL TEST TO FDA FOR EMERGENCY USE AUTHORIZATION